Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
Thursday, April 23, 2026 1 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc will report its first quarter 2026 financial results on April 28, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time. Participants can register for the call and access a replay afterward. Kiniksa focuses on developing therapies for unmet medical needs.
Price reaction · baseline $43.04 (2026-04-22 close) · hit after-hours · 1 other KNSA headline(s) in the window, move may be shared
day 0 close
0%
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is actively engaging with investors.
The company is focused on addressing unmet medical needs.
Upcoming financial results may indicate strong portfolio performance.
Full Press Release Details
LONDON, April 23, 2026 (GLOBE NEWSWIRE) --Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website atwww.kiniksa.com. Individuals interested in participating in the call via telephone may registerhere. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visitwww.kiniksa.com.